Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden muscle decline: how often does MS rob patients of strength?

NCT ID NCT07842731

Knowledge-focused Sponsor: Atılım University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are studying how common sarcopenia (muscle loss) and dynapenia (muscle weakness) are in people with multiple sclerosis, and whether these problems become more frequent as disability increases. About 150 adults with MS will be grouped by disability level, from mild to moderate, based on their EDSS scores. The team will measure muscle mass, handgrip strength, and standing speed, and also check physical activity, fatigue, and independence in daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers map how muscle loss tracks with MS disability, doctors could screen for it earlier and design rehabilitation or nutrition programs to protect strength and independence.
What could go wrong
This study only observes people at one point in time, so it cannot prove that MS causes muscle loss or that treating muscle loss changes disability. Results from 150 patients may not apply to everyone with MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 150 adults diagnosed with multiple sclerosis (MS) receiving care at the Physiotherapy and Rehabilitation Unit of Başkent University Hospital. Participants will be classified into mild (EDSS \<4.0) and moderate (EDSS 4.0-6.5) disability groups.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * Diagnosed with multiple sclerosis (MS) by a neurologist. * Standardized Mini-Mental State Examination (SMMSE) score ≥24. * Expanded Disability Status Scale (EDSS) score ≤6.5. * Willing to participate and provide written informed consent. Exclusion Criteria: * Orthopedic surgery within the previous 3 months. * Botulinum toxin injection within the previous 3 months. * Severe cognitive impairment affecting the ability to complete assessments. * Severe cardiopulmonary disease. * Serious orthopedic or additional neurological conditions that may affect the assessments. * Severe pain (Visual Analog Scale \[VAS\] score \>7).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dynapenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fatigue Motor Activity multiple sclerosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dynapenia Multiple sclerosis Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baskent University Ankara Hospital

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.